NasdaqCM - Delayed Quote USD

Edesa Biotech, Inc. (EDSA)

4.3101 -0.1099 (-2.49%)
At close: 12:02 PM EDT
4.4600 +0.15 (+3.48%)
After hours: 4:02 PM EDT
Currency in USD All numbers in thousands
Download
Breakdown
TTM
9/30/2023
9/30/2022
9/30/2021
9/30/2020
Total Revenue
--
--
--
--
328.8010
Cost of Revenue
--
--
--
--
17.6010
Gross Profit
--
--
--
--
311.2000
Operating Expense
8,000.0090
8,641.7190
17,590.5330
13,340.4930
6,712.0420
Operating Income
-8,000.0090
-8,641.7190
-17,590.5330
-13,340.4930
-6,400.8420
Net Non Operating Interest Income Expense
301.3830
289.8460
63.5230
11.1650
37.7780
Other Income Expense
-18.6230
-21.7420
-21.1140
-13.0220
-0.3660
Pretax Income
-7,717.2490
-8,373.6150
-17,548.1240
-13,342.3500
-6,363.4300
Tax Provision
--
0.8000
0.8000
0.8000
0.8000
Net Income Common Stockholders
-7,718.0490
-8,374.4150
-17,548.9240
-13,343.1500
-6,364.2300
Diluted NI Available to Com Stockholders
-7,718.0490
-8,374.4150
-17,548.9240
-13,343.1500
-6,364.2300
Basic EPS
-20.16
-20.51
-8.37
-7.70
-5.18
Diluted EPS
-20.16
-20.51
-8.37
-7.70
-5.18
Basic Average Shares
533.7120
408.4180
2,096.4450
1,725.4030
1,229.5940
Diluted Average Shares
533.7120
408.4180
2,096.4450
1,725.4030
1,229.5940
Total Operating Income as Reported
-8,701.8820
-9,222.7580
-18,370.7900
-23,681.3320
-6,400.8420
Total Expenses
8,000.0090
8,641.7190
17,590.5330
13,340.4930
6,729.6430
Net Income from Continuing & Discontinued Operation
-7,718.0490
-8,374.4150
-17,548.9240
-13,343.1500
-6,364.2300
Normalized Income
-7,699.4260
-8,361.3698
-17,533.3440
-13,333.5788
-6,363.9610
Interest Income
301.3830
289.8460
63.5230
11.1650
37.7780
Net Interest Income
301.3830
289.8460
63.5230
11.1650
37.7780
EBIT
-8,000.0090
-8,641.7190
-17,590.5330
-13,340.4930
-6,400.8420
EBITDA
-7,798.7040
-8,458.2480
-17,472.3450
-13,221.7050
-6,343.2790
Reconciled Cost of Revenue
--
--
--
--
17.6010
Reconciled Depreciation
201.3050
183.4710
118.1880
118.7880
57.5630
Net Income from Continuing Operation Net Minority Interest
-7,718.0490
-8,374.4150
-17,548.9240
-13,343.1500
-6,364.2300
Total Unusual Items Excluding Goodwill
-18.6230
-21.7420
-21.1140
-13.0220
-0.3660
Total Unusual Items
-18.6230
-21.7420
-21.1140
-13.0220
-0.3660
Normalized EBITDA
-7,780.0810
-8,436.5060
-17,451.2310
-13,208.6830
-6,342.9130
Tax Rate for Calcs
--
0.0004
0.0003
0.0003
0.0003
Tax Effect of Unusual Items
--
-8.6968
-5.5340
-3.4508
-0.0970
9/30/2020 - 6/21/2010

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

TVGN Tevogen Bio Holdings Inc.
1.0000
+17.65%
 
PSTV Plus Therapeutics, Inc.
1.6900
+1.81%
 
NLSP NLS Pharmaceutics Ltd.
0.1419
+7.18%
 
VCNX Vaccinex, Inc.
5.83
-0.94%
 
INDP Indaptus Therapeutics, Inc.
2.1100
-3.21%
 
SXTP 60 Degrees Pharmaceuticals, Inc.
0.2358
-1.26%
 
CHRO Chromocell Therapeutics Corporation
1.6000
+6.67%
 
FWBI First Wave BioPharma, Inc.
2.7400
+0.37%
 
NNVC NanoViricides, Inc.
1.1000
-0.90%
 
FNCH Finch Therapeutics Group, Inc.
2.3200
+3.11%